VAL.L Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 07:20):

Stats
Today's Volume	415 880
Average Volume	777 955
Market Cap	4.36M
EPS	£0 ( 2023-08-24 )
Next earnings date	( £0 ) 2024-06-03
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-1.100
ATR14	£0 (0.00%)

ValiRx PLC Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ValiRx PLC Financials

Annual	2022
Revenue:	£0
Gross Profit:	£-224 268 (0.00 %)
EPS:	£-0.0311

Q2	2023
Revenue:	£0
Gross Profit:	£-118 220 (0.00 %)
EPS:	£-0.0103

Q4	2022
Revenue:	£0
Gross Profit:	£-117 418 (0.00 %)
EPS:	£-0.0154

Q2	2022
Revenue:	£0
Gross Profit:	£-106 850 (0.00 %)
EPS:	£-0.0153

Financial Reports:

No articles found.

ValiRx PLC

ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a small molecule that has completed Phase I/II trials for the treatment of prostate cancer and other hormone associated solid tumours comprising breast and ovarian cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of women with endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Hatfield, the United Kingdom.